Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

MDS 2020 | Future MDS treatment options

Inga Mandac-Smoljanovic • 5 Mar 2020
MDS 2020
Myelodysplastic Syndromes Azacitidine

Inga Mandac, MD, Clinical Hospital Merkur, Zagreb, Croatia, discusses future priorities to focus on combinational treatments with targeted agents or monoclonal antibodies for myelodysplastic syndromes (MDS). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from Inga Mandac-Smoljanovic

Managing the cardiac off-target side effects associated with ibrutinib treatment
2:20
Managing the cardiac off-target side effects associated with ibrutinib treatment
Inga Mandac-Smoljanovic • 14 Sep 2025
Case report: the continued efficacy of low-dose ibrutinib for CLL after 10 years of treatment
1:31
Case report: the continued efficacy of low-dose ibrutinib for CLL after 10 years of treatment
Inga Mandac-Smoljanovic • 14 Sep 2025
Factors affecting the dose of ibrutinib administered to patients with CLL
2:01
Factors affecting the dose of ibrutinib administered to patients with CLL
Inga Mandac-Smoljanovic • 14 Sep 2025
MicroRNA signatures in MDS
2:51
MicroRNA signatures in MDS
Inga Mandac-Smoljanovic • 5 Mar 2020

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Inga Mandac-Smoljanovic • 6 Dec 2025
Practice-changing highlights in MDS from ASH 2025: the VERONA trial and triplet combinations
1:07
Practice-changing highlights in MDS from ASH 2025: the VERONA trial and triplet combinations
Inga Mandac-Smoljanovic • 6 Dec 2025
Outcomes of HMA plus venetoclax in HR-MDS: an analysis from the icMDS validate database
5:58
Outcomes of HMA plus venetoclax in HR-MDS: an analysis from the icMDS validate database
Inga Mandac-Smoljanovic • 16 Dec 2025
Olutasidenib with co-targeted therapy in R/R IDH1-mutated myeloid malignancies: Phase II trial
1:30
Olutasidenib with co-targeted therapy in R/R IDH1-mutated myeloid malignancies: Phase II trial
Inga Mandac-Smoljanovic • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals